GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works

Globalization of Diabetes

Hu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954 · see citing works

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706 · see citing works

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · see citing works

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596 · see citing works

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial

Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · see citing works

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · see citing works

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · see citing works

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · see citing works

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 422 · see citing works

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · see citing works

GLP-1 Receptor Expression Within the Human Heart

Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · see citing works

Exenatide Exerts a Potent Antiinflammatory Effect

Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284 · see citing works

Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives

Stefanadis, C., Antoniou, C. K., Tsiachris, D., & Pietri, P. G. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005543 · Cited by 279 · see citing works

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262 · see citing works

Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

DeYoung, M. B., MacConell, L., Sarin, V., TRAUTMANN, M. E., & Herbert, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0050 · Cited by 242 · see citing works

Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels

Costantino, S., Paneni, F., Battista, R., Castello, L., Capretti, G., Chiandotto, S., Tanese, L., Russo, G., Pitocco, D., Lanza, G. A., et al. (2017) · Diabetes · doi:10.2337/db17-0294 · Cited by 188 · see citing works

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

Bush, M., Matthews, J. E., Boever, E. H. D., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Gutierrez, M., & Stewart, M. W. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00992.x · Cited by 180 · see citing works

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158 · see citing works

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

Diamant, M., Gaal, L. V., Guerci, B., Stranks, S. N., Han, J., Malloy, J. L., Boardman, M. K., & TRAUTMANN, M. E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70029-4 · Cited by 152 · see citing works

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · see citing works

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE ^−/− mouse model

Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148 · see citing works

Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial

Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143 · see citing works

The Cardiovascular Effects of GLP‐1 Receptor Agonists

Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 136 · see citing works

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study

Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135 · see citing works

Cytokines: Roles in Atherosclerosis Disease Progression and Potential Therapeutic Targets

Moss, J. W. E., & Ramji, D. P. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0072 · Cited by 126 · see citing works

Oxidized Low-Density Lipoprotein Contributes to Atherogenesis via Co-activation of Macrophages and Mast Cells

Chen, C., & Khismatullin, D. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123088 · Cited by 113 · see citing works

Liraglutide Reduces Oxidative Stress and Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

Rizzo, M., Abate, N., Chandalia, M., Rizvi, A. A., Giglio, R. V., Nikolic, D., Marino Gammazza, A., Barbagallo, I., Isenovic, E. R., Banach, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2291 · Cited by 113 · see citing works

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

Rizzo, M., Chandalia, M., Patti, A. M., Bartolo, V. D., Rizvi, A. A., Montalto, G., & Abate, N. I. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 107 · see citing works

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104 · see citing works

Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk

Scirica, B. M., Bhatt, D. L., D, E. B. M., Raz, I., Cavender, M. A., Im, K., Mosenzon, O., Udell, J. A., Hirshberg, B., Pollack, P. S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3030 · Cited by 102 · see citing works

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice

Orgaard, A., & Holst, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4315-2 · Cited by 102 · see citing works

Microvascular Function Contributes to the Relation Between Aortic Stiffness and Cardiovascular Events

Cooper, L. L., Palmisano, J. N., Benjamin, E. J., Larson, M. G., Vasan, R. S., Mitchell, G. F., & Hamburg, N. M. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.004979 · Cited by 97 · see citing works

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Bentley–Lewis, R., Aguilar, D. A., Riddle, M. C., Claggett, B. L., Díaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L., Lawson, F. C., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 96 · see citing works

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

Henry, R. R., Rosenstock, J., Logan, D. K., Alessi, T. R., Luskey, K. L., & Baron, M. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.12.009 · Cited by 81 · see citing works

Non‐ST‐elevation myocardial infarction outcomes in patients with type 2 diabetes with non‐obstructive coronary artery stenosis: Effects of incretin treatment

Marfella, R., Sardu, C., Calabrò, P., Siniscalchi, M., Minicucci, F., Signoriello, G., Balestrieri, M. L., Mauro, C., Rizzo, M. R., Paolisso, G., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13122 · Cited by 80 · see citing works

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis

Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76 · see citing works

Current perspectives on cardiovascular outcome trials in diabetes

on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 74 · see citing works

Lifestyle precision medicine: the next generation in type 2 diabetes prevention?

Mutie, P. M., Giordano, G. N., & Franks, P. W. (2017) · BMC Medicine · doi:10.1186/s12916-017-0938-x · Cited by 72 · see citing works

Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium

Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 70 · see citing works

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes

Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68 · see citing works

Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes

Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 65 · see citing works

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the duration trials

Grimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C. T., Dong, H., & Malloy, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2660 · Cited by 63 · see citing works

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

Ferdinand, K. C., Botros, F. T., Atisso, C. M., & Sager, P. T. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0355-z · Cited by 61 · see citing works

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

on behalf of the LEADER investigators, Masmiquel, L., Leiter, L. A., Vidal, J., Bain, S. C., Petrie, J. R., Franek, E., Raz, I., Comlekci, A., Jacob, S., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0341-5 · Cited by 57 · see citing works

Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors

Stonehouse, A. H., Okerson, T. E., Kendall, D. M., & Maggs, D. G. (2008) · Current Diabetes Reviews · doi:10.2174/157339908784220705 · Cited by 54 · see citing works

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg

Mancini, M. C., & de Melo, M. E. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0242-0 · Cited by 54 · see citing works

Updates on cardiovascular outcome trials in diabetes

on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0610-y · Cited by 52 · see citing works

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study

Rizvi, A. A., Patti, A. M., Giglio, R. V., Nikolić, D., Amato, A., Busaidi, N. A., Al‐Rasadi, K., Soresi, M., Banach, M., Montalto, G., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1067299 · Cited by 52 · see citing works

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

Kadowaki, T., Namba, M., Imaoka, T., Yamamura, A., Goto, W., Boardman, M. K., & Sowa, H. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00084.x · Cited by 50 · see citing works

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis

Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48 · see citing works

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43 · see citing works

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

Torimoto, K., Okada, Y., Mori, H., Otsuka, T., Kawaguchi, M., Matsuda, M., Kuno, F., Sugai, K., Sonoda, S., Hajime, M., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0188-1 · Cited by 43 · see citing works

Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes

Herzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 41 · see citing works

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

Rizzo, M., Nikolić, D., Banach, M., Patti, A. M., Montalto, G., & Rizvi, A. A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131206102255 · Cited by 36 · see citing works

The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective

Rizzo, M., Nikolić, D., Banach, M., Giglio, R. V., Patti, A. M., Bartolo, V. D., Tamburello, A., Zabbara, A., Pecoraro, G., Montalto, G., et al. (2013) · Clinical Lipidology · doi:10.2217/clp.13.8 · Cited by 33 · see citing works

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Engelbrechtsen, L., Lundgren, J. R., Albrechtsen, N. J. W., Mahendran, Y., Iepsen, E. W., Finocchietto, P. V., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., et al. (2017) · Obesity Science & Practice · doi:10.1002/osp4.133 · Cited by 32 · see citing works

Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting

Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0090 · Cited by 28 · see citing works

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25 · see citing works

Effects of liraglutide on hemodynamic parameters in patients with heart failure

Zhang, J. Y., Wang, X. Y., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18570 · Cited by 25 · see citing works

Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.

Fala, L. (2015) · PubMed · Cited by 23 · see citing works

Albiglutide: a unique GLP-1 receptor agonist

Rendell, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 23 · see citing works

Effects of Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hipanic Populations: Subgroup Analysis from Scale Randomized Trials

O'Neil, P. M., Garvey, W. T., González-Campoy, J. M., Mora, P., Ortíz, R. V., Guerrero, G., Claudius, B., & Pi-Sunyer, X. (2016) · Endocrine Practice · doi:10.4158/ep151181.or · Cited by 22 · see citing works

Baseline factors associated with glycaemic response to treatment with once‐weekly dulaglutide in patients with type 2 diabetes

Wysham, C., Guerci, B., D’Alessio, D. A., Jia, N., & Botros, F. T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12702 · Cited by 20 · see citing works

Non-glycemic effects of pioglitazone and incretin-based therapies

Rizzo, M., Avogaro, A., Montalto, G., & Rizvi, A. A. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.804067 · Cited by 11 · see citing works

Medicinal Chemistry of Novel Anti-Diabetic Drugs

Adeghate, E. A. (2011) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501105010068 · Cited by 9 · see citing works

Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)

Milosevski, V., Åhrén, B., Masmiquel, L., Kumar, H., Sargın, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. C. C. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.018 · Cited by 6 · see citing works

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)

Harasfflma, S.-I., SORLI, C. H., Tsoukas, G. M., Unger, J. R., Karsbøl, J. D., Hansen, T. K., & Bain, S. C. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(16)31226-8 · Cited by 4 · see citing works

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus

Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 4 · see citing works

Oral Antidiabetic Agents and Cardiovascular Outcomes

Pareek, M., & Bhatt, D. L. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.07.003 · Cited by 4 · see citing works

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441 · see citing works

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · see citing works

Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics

Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188 · see citing works

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164 · see citing works

COVID-19 and diabetes: The why, the what and the how

Cuschieri, S., & Grech, S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107637 · Cited by 152 · see citing works

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL

Vekić, J., Zeljković, A., Cicero, A. F. G., Janež, A., Stoian, A. P., Sönmez, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58020299 · Cited by 150 · see citing works

Metabolic syndrome-related kidney injury: a review and update

Lin, L., Tan, W., Pan, X., Tian, E., Wu, Z., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.904001 · Cited by 139 · see citing works

COVID-19 and diabetes management: What should be considered?

Ceriello, A., Stoian, A. P., & Rizzo, M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108151 · Cited by 122 · see citing works

Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis

Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence

Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 99 · see citing works

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0942-x · Cited by 94 · see citing works

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

Ceriello, A., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Schnell, O., Škrha, J., & Valensi, P. E. (2020) · Diabetes Care · doi:10.2337/dc20-0941 · Cited by 88 · see citing works

The menopausal transition period and cardiovascular risk

Mehta, J. M., & Manson, J. E. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00926-7 · Cited by 96 · see citing works

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective

Michałowska, J. M., Miller‐Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 69 · see citing works

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide

Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02319-7 · Cited by 66 · see citing works

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes

Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 67 · see citing works

Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention

Schwarz, P. E. H., Timpel, P., Harst, L., Greaves, C. J., Ali, M. K., Lambert, J. D., Weber, M. B., Almedawar, M. M., & Morawietz, H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.081 · Cited by 65 · see citing works

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

Zobel, E. H., Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V., Kjaer, A., Hansen, T. W., Rossing, P., & Størling, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97967-0 · Cited by 59 · see citing works

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes

Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 58 · see citing works

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58 · see citing works

Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials

Caruso, I., Cignarelli, A., & Giorgino, F. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.07.004 · Cited by 57 · see citing works

Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance

DiNicolantonio, J. J., McCarty, M. F., & O’Keefe, J. H. (2019) · Open Heart · doi:10.1136/openhrt-2018-000890 · Cited by 56 · see citing works

The effect of <scp>GLP</scp> ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis

Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59 · see citing works

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity

Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56 · see citing works

Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?

Domingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 61 · see citing works

Novel Therapeutical Approaches to Managing Atherosclerotic Risk

Giglio, R. V., Stoian, A. P., Al‐Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 54 · see citing works

Future perspectives of the pharmacological management of diabetic dyslipidemia

Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 54 · see citing works

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54 · see citing works

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

Giglio, R. V., Nikolić, D., Volti, G. L., Stoian, A. P., Banerjee, Y., Magán‐Fernández, A., Castellino, G., Patti, A. M., Chianetta, R., Castracani, C. C., et al. (2020) · Metabolites · doi:10.3390/metabo10100391 · Cited by 53 · see citing works

Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns

Koliaki, C. C., Tentolouris, A., Eleftheriadou, I., Melidonis, A. J., Dimitriadis, G., & Tentolouris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072288 · Cited by 54 · see citing works

The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus

Bonilha, I., Hajduch, É., Luchiari, B., Nadruz, W., Goff, W. L., & Sposito, A. C. (2021) · Metabolites · doi:10.3390/metabo11120807 · Cited by 55 · see citing works

Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives

Mesa, F., Magán‐Fernández, A., Castellino, G., Chianetta, R., Nibali, L., & Rizzo, M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.001 · Cited by 51 · see citing works

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options

Rizvi, A. A., Stoian, A. P., Janež, A., & Rizzo, M. (2021) · Biomedicines · doi:10.3390/biomedicines9111579 · Cited by 50 · see citing works

Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice

Han, F., Hou, N., Liu, Y., Huang, N., Pan, R., Zhang, X., Mao, E.-W., & Sun, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109537 · Cited by 47 · see citing works

The Role of Fructose as a Cardiovascular Risk Factor: An Update

Busnatu, Ș., Salmen, T., Pană, M.-A., Rizzo, M., Stallone, T., Παπάνας, Ν., Popovic, D. S., Tănăsescu, D., Şerban, D., & Stoian, A. P. (2022) · Metabolites · doi:10.3390/metabo12010067 · Cited by 47 · see citing works

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

Vekić, J., Zeljković, A., Stefanović, A., Giglio, R. V., Ciaccio, M., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212409 · Cited by 46 · see citing works

Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study

Popoviciu, M. S., Marin, V. N., Vesa, C. M., Ștefan, S., Stoica, R. A., Serafinceanu, C., Merlo, E. M., Rizvi, A. A., Rizzo, M., Busnatu, Ș., et al. (2022) · Healthcare · doi:10.3390/healthcare10010174 · Cited by 46 · see citing works

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group

Janež, A., Muzurović, E. M., Stoian, A. P., Haluzı́k, M., Guja, C., Czupryniak, L., Duvnjak, L. S., Lalic, N. M., Tankova, T. I., Bogdański, P., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.017 · Cited by 42 · see citing works

Coronary Heart Disease in Type 2 Diabetes Mellitus: Genetic Factors and Their Mechanisms, Gene-Gene, and Gene-Environment Interactions in the Asian Populations

Zarkasi, K. A., Murad, N. A. A., Ahmad, N., Jamal, R., & Abdullah, N. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020647 · Cited by 38 · see citing works

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38 · see citing works

The Role of Endothelium in COVID-19

Ionescu, M., Stoian, A. P., Rizzo, M., Şerban, D., Nuzzo, D., Mazilu, L., Suceveanu, A., Dascălu, A. M., & Parepa, I. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111920 · Cited by 39 · see citing works

Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials

Patoulias, D., Popovic, D. S., Stoian, A. P., Janež, A., Sahebkar, A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108529 · Cited by 36 · see citing works

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update

Giglio, R. V., Patti, A. M., Rizvi, A. A., Stoian, A. P., Ciaccio, M., Παπάνας, Ν., Janež, A., Sönmez, A., Banach, M., Sahebkar, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020291 · Cited by 33 · see citing works

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Karakasis, P., Fragakis, N., Κούσκουρας, Κ., Karamitsos, T. D., Patoulias, D., & Rizzo, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.010 · Cited by 34 · see citing works

Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies

Al-Hashmi, K., Giglio, R. V., Stoian, A. P., Patti, A. M., Waili, K. A., Al‐Rasadi, K., Ciaccio, M., & Rizzo, M. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1355732 · Cited by 32 · see citing works

Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence

Karakasis, P., Patoulias, D., Kassimis, G., Koufakis, T., Klisic, A. N., Doumas, M. N., Fragakis, N., & Rizzo, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128304097240529053538 · Cited by 32 · see citing works

Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy

Ma, L., Liu, D., Yu, Y., Li, Z., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1587806 · Cited by 32 · see citing works

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

Stoian, A. P., Παπάνας, Ν., Prázný, M., Rizvi, A. A., & Rizzo, M. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420937868 · Cited by 32 · see citing works

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes

Patti, A. M., Giglio, R. V., Allotta, A., Bruno, A., Bella, T. D., Stoian, A. P., Ciaccio, M., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051362 · Cited by 32 · see citing works

Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT ‐2 inhibitors and GLP ‐1 receptor agonists

Bonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 32 · see citing works

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies

Vekić, J., Zeljković, A., Al‐Rasadi, K., Cesur, M., Silva‐Nunes, J., Stoian, A. P., & Rizzo, M. (2022) · Metabolites · doi:10.3390/metabo12020108 · Cited by 30 · see citing works

Lipid effects of glucagon-like peptide 1 receptor analogs

Berberich, A. J., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000750 · Cited by 30 · see citing works

An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)

Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312527 · Cited by 32 · see citing works

Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes

Pan, X., Yang, L., Wang, S., Liu, Y., Yue, L., & Chen, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110196 · Cited by 30 · see citing works

Effect of Peanut Consumption on Cardiovascular Risk Factors: A Randomized Clinical Trial and Meta-Analysis

Parilli‐Moser, I., Hurtado‐Barroso, S., Guasch‐Ferré, M., & Lamuela-Raventós, R. M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.853378 · Cited by 28 · see citing works

Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis

Albulushi, A., Tanoh, D. B., Almustafa, A., Matrooshi, N. A., Zolty, R., & Lowes, B. D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02415-8 · Cited by 29 · see citing works

The Role of Advanced Glycation End Products on Dyslipidemia

Vekić, J., Vujčić, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al‐Rasadi, K., Stoian, A. P., Zeljković, A., & Rizzo, M. (2023) · Metabolites · doi:10.3390/metabo13010077 · Cited by 30 · see citing works

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Ferrannini, G., Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Díaz, R., Dyal, L., Lakshmanan, M. C., Mellbin, L., Probstfield, J. L., Riddle, M. C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa777 · Cited by 28 · see citing works

The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism

Banerjee, Y., Stoian, A. P., Silva‐Nunes, J., Sönmez, A., Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1970744 · Cited by 28 · see citing works

A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine

Xia, J., Li, Q., Liu, Y., Ren, Q., Gao, J., Tian, Y., Li, J., Zhang, B., Sun, H., & Liu, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00372 · Cited by 27 · see citing works

Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review

Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 29 · see citing works

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure

Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26 · see citing works

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)

Janić, M., Rizzo, M., Cosentino, F., Stoian, A. P., Lunder, M., Šabović, M., & Janež, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01226-y · Cited by 26 · see citing works

Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study

Hong, A. T., Luu, I. Y.-K., Lin, F., Shin, L., Hsu, C., Shih, C.-D., Armstrong, D. G., & Tan, T. (2025) · Diabetes Care · doi:10.2337/dc25-0292 · Cited by 25 · see citing works

The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis

Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 25 · see citing works

Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives

Cătoi, A. F., Vodnar, D. C., Corina, A., Nikolić, D., Citarrella, R., Pérez‐Martínez, P., & Rizzo, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708190437 · Cited by 25 · see citing works

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Uneda, K., Kawai, Y., Yamada, T., Kinguchi, S., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-89620-7 · Cited by 25 · see citing works

GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty?

Verhey, J. T., Austin, R. P., Tarabichi, S., Paul, B., Deckey, D. G., Christopher, Z. K., Spangehl, M. J., & Bingham, J. S. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.03.012 · Cited by 24 · see citing works

Diabetes and Vascular Disease: Is It All About Glycemia?

Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 23 · see citing works

Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management

Ferrannini, G., Norhammar, A., Gyberg, V., Mellbin, L., & Rydén, L. (2020) · Diabetes Care · doi:10.2337/dci20-0002 · Cited by 23 · see citing works

Secreted frizzled-related protein 2 ameliorates diabetic cardiomyopathy by activating mitophagy

Zheng, H., Li, W., Huang, G., Zhu, H., Wen, W., Liu, X., Sun, L., Ma, T., Huang, X., Hu, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166989 · Cited by 21 · see citing works

Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trial

Sun, L., Yuan, Y., Li, Y., & Rao, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11948 · Cited by 21 · see citing works

The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review

Manosroi, W., Phudphong, P., Atthakomol, P., & Phimphilai, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01135-y · Cited by 20 · see citing works

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes

Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 19 · see citing works

Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome

Premji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18 · see citing works

Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment

Vekić, J., Silva‐Nunes, J., & Rizzo, M. (2022) · Metabolites · doi:10.3390/metabo12080712 · Cited by 18 · see citing works

Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials

Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 16 · see citing works

Is diabetes mellitus a wrongdoer to COVID-19 severity?

Sarkar, S., Das, D., Wann, S. B., Kalita, J., & Manna, P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108936 · Cited by 17 · see citing works

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01170-3 · Cited by 17 · see citing works

Anti-atherosclerotic effect of incretin receptor agonists

Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 19 · see citing works

Group-Based Lifestyle Intervention Strategies for Metabolic Syndrome: A Scoping Review and Strategic Framework for Future Research

Mahadzir, M. D. A., Quek, K. F., & Ramadas, A. (2021) · Medicina · doi:10.3390/medicina57111169 · Cited by 16 · see citing works

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )

Wilson, L., Zhao, Z., Divino, V. M., Bassan, M., Hartaigh, B. Ó., Stensen, S., & Özer, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70436 · Cited by 15 · see citing works

GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?

Muzurović, E. M., Yumuk, V., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108647 · Cited by 15 · see citing works

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Nowak, M., Nowak, W., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0029 · Cited by 15 · see citing works

Diabetes in COVID-19 patients: challenges and possible management strategies

Reshad, R. A. I., Riana, S. H., Chowdhury, M. A.-B., Moin, A. T., Miah, F., Sarkar, B., & Jewel, N. A. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00099-2 · Cited by 13 · see citing works

Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection

Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 13 · see citing works

From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists

Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 12 · see citing works

Effect of hypertension and diabetes on subclinical left ventricular systolic dysfunction in a predominantly elderly population-based cohort

Mannina, C. M., Jin, Z., Russo, C. A., Homma, S., Elkind, M. S. V., Rundek, T., Lee, T. C., Matsumoto, K., Shames, S., Sacco, R. L., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319872571 · Cited by 12 · see citing works

Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence

Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 11 · see citing works

The COVID-19 pandemic and diabetes mellitus

Papazafiropoulou, A. K., & Antonopoulos, S. (2020) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2020.97435 · Cited by 11 · see citing works

Anthocyanin Extract of Purple Corn Improves Hyperglycemia and Insulin Resistance of Rats Fed High Fat and Fructose Diet via GLP1 and GLP1R Mechanism

Chayati, I., Sunarti, S., Marsono, Y., & Astuti, M. (2019) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-7-4-7 · Cited by 11 · see citing works

Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes

Yang, J., Le, Y., Wei, T., Wang, K., Yang, K., Xiao, W., Hong, T., & Wei, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107797 · Cited by 10 · see citing works

Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis

Wang, C., Chen, J., Wang, P., Qing, S., Li, W., & Lu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.821028 · Cited by 9 · see citing works

Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections

Rizvi, A. A., Linhart, A., Vrablı́k, M., Liberopoulos, E. N., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2043848 · Cited by 9 · see citing works

Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs – The CAPISCO International Expert Panel

Popovic, D. S., Παπάνας, Ν., Koufakis, T., Kotsa, K., Almahmeed, W. A., Al‐Rasadi, K., Al-Alawi, K., Banach, M., Banerjee, Y., Ceriello, A., et al. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2019-1111 · Cited by 8 · see citing works

A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure

Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 9 · see citing works

Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues

Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212311 · Cited by 8 · see citing works

The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance

Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8 · see citing works

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

Krishnan, S., Srivastava, P. K., Attaluri, J., Nayeri, R., Chatterjee, D., Patel, J., Nsair, A., Budoff, M. J., & Nayeri, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12010019 · Cited by 7 · see citing works

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299 · see citing works

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction

Lorber, D. (2012) · Cardiovascular Therapeutics · doi:10.1111/cdr.12000 · Cited by 11 · see citing works

Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs

Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66 · see citing works

Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials

Marx, N. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa174 · Cited by 9 · see citing works

Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes

BAJAJ, H. S., Aljabri, B. A., & Verma, S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000562 · Cited by 13 · see citing works